A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.
about
B-cell survival factors in autoimmune rheumatic disordersDrugs for discoid lupus erythematosus.Failure of a systemic lupus erythematosus response index developed from clinical trial data: lessons examined and learned.Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.Mouse Models of Primary Sjogren's Syndrome.Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.Impact of standard of care treatments and disease variables on outcomes in systemic lupus erythematosus trials: analysis from the Lupus Foundation of America Collective Data Analysis InitiativeInhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE).Drugs in early clinical development for Systemic Lupus Erythematosus.Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus ErythematosusSpotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to dateBiologic therapies in systemic lupus erythematosus.Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration.Lupus nephritis and B-cell targeting therapy.Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art.Emerging therapies in systemic lupus erythematous: from clinical trial to the real life.Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases.Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus.Recent advances and current state of immunotherapy in systemic lupus erythematosus.Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser.Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab.The safety of pharmacological treatment options for lupus nephritis.Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials.Update on Biologic Therapies for Systemic Lupus Erythematosus.Immunomodulators in SLE: Clinical evidence and immunologic actions.Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus.Why targeted therapies are necessary for systemic lupus erythematosus.B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases.Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE.Systemic lupus erythematosus biomarkers: the challenging quest.Brief Report: Longitudinal Patterns of Response to Standard of Care Therapy for Systemic Lupus Erythematosus: Implications for Clinical Trial Design.Novel Treatments in Lupus.Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective.Real life experience on the effect of Belimumab in patients with active systemic lupus.The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials.Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon ActivityEfficacy and Safety of Atacicept in Patients with Systemic Lupus Erythematosus: Results of a 24-week Randomized, Placebo-Controlled, Phase IIb Study.Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index.
P2860
Q26796484-7D219CE9-6819-4949-AC11-38FAC2309A87Q30234556-DC889588-5DD4-47D9-9BC4-8929C94AB55EQ31160251-09341B6D-2D77-41E4-8B84-4ADE097F1B44Q33698040-753D8707-D6F2-401C-8D21-2FD6EC1EC3EAQ33731705-2D7FA323-2FEB-4E8E-A139-3EE68F6DF300Q35587450-5C100D6A-7785-4B37-9C4B-F1032CE5220FQ35986113-DAB3D9DF-79D2-4685-AD55-8CE4540D7690Q36154537-D568B6B4-A05E-4B49-896E-46BC1720C483Q36271212-514EC308-F1F8-4471-BE27-C0C612CB74B3Q37324772-E140CAFE-09B0-4457-928A-67FDAD5A7BBFQ37633408-0FDE8C52-21C5-4305-9466-07A5207E884CQ37709763-F085040C-9F06-4B09-A61F-3FFA28C8D47FQ38425831-B10BE675-B7D7-4EF4-88C0-974868E025F9Q38605480-5410AC69-774D-4116-B206-D2D8569B0F23Q38643755-0EEF040E-F3C2-447E-BDEF-525CF51897C0Q38690844-F8D54147-2393-45D1-806A-A1D0A8994CB0Q38747383-6A76F4DF-E987-4EF2-87E8-70D64AFDF0B0Q38755707-84CEA3D4-E35B-4F75-B76C-FA6198A21817Q38771936-42F9E127-DD92-478D-8573-F443CA5FF1E3Q38794663-13305344-8CFB-4662-85B3-B0B3A71955B6Q38799791-60297F9B-E272-43C1-A413-0AD50041ADC9Q38813080-A27728FE-8BA6-4557-BE4E-54CDD4F4878CQ38829637-E4FF67D4-1330-45F2-AFD3-5299293ABDEBQ38840646-C54BFBD9-2DF0-4994-BB56-ABA3A7940895Q38864797-F2D5CD08-1F09-475B-8533-3F2C7EAC3279Q38883883-C627AA23-87D5-4DA5-A3B1-53BC147FF093Q38888137-74DAA96E-AE76-47E7-83AC-5250CF4B9955Q38920435-42CC6072-B662-40A5-87FF-34B1CC43CBE0Q38961202-88AB5AF6-BC9E-4FF1-928B-8471E43D6B97Q38979169-C5B1B0F7-69E2-4872-B453-0988BCAF3826Q39053118-55746BA6-93D3-4669-9018-9183C6F03688Q39088664-FDE2E50A-EFAA-41E1-9C1F-7DFA91A7D577Q39164953-5A16D3A6-91C6-4468-9A5B-362141FC76BFQ39218839-81473578-F0CF-4960-BC69-96C680AAA89BQ39379152-C2C5727C-966C-452E-BD2B-17DE50D444C3Q39953054-BD675E04-0F41-45C5-9869-762197FAA52FQ40309561-BC6892FC-C8DF-4988-88D9-D74FB5BB8811Q41692822-47BC15A2-FFA3-4C1E-8308-9B3BF28D1EC8Q46083219-42450915-50A6-473F-A859-1D6F4E2B4D83Q46803412-AD93AB40-048F-4690-8529-47A73062DE0F
P2860
A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A phase 2, randomised, placebo ...... hematosus, the PEARL-SC study.
@ast
A phase 2, randomised, placebo ...... hematosus, the PEARL-SC study.
@en
A phase 2, randomised, placebo ...... hematosus, the PEARL-SC study.
@nl
type
label
A phase 2, randomised, placebo ...... hematosus, the PEARL-SC study.
@ast
A phase 2, randomised, placebo ...... hematosus, the PEARL-SC study.
@en
A phase 2, randomised, placebo ...... hematosus, the PEARL-SC study.
@nl
prefLabel
A phase 2, randomised, placebo ...... hematosus, the PEARL-SC study.
@ast
A phase 2, randomised, placebo ...... hematosus, the PEARL-SC study.
@en
A phase 2, randomised, placebo ...... hematosus, the PEARL-SC study.
@nl
P2093
P2860
P921
P1476
A phase 2, randomised, placebo ...... hematosus, the PEARL-SC study.
@en
P2093
M A Scheinberg
PEARL-SC Study
R S Martin
P2860
P304
P356
10.1136/ANNRHEUMDIS-2013-205144
P407
P577
2014-04-19T00:00:00Z